Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:GHRSNASDAQ:LXEONASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.66-3.1%$8.73$3.61▼$13.85$790.67M1.541.13 million shs4.58 million shsGHRSGH Research$10.42-3.5%$10.31$6.00▼$20.50$542.13M0.86175,798 shs70,405 shsLXEOLexeo Therapeutics$2.69-10.3%$3.06$1.45▼$19.50$89.30M1.27460,687 shs980,393 shsTYRATyra Biosciences$10.09+0.2%$9.64$6.42▼$29.60$535.68M1.17259,260 shs394,066 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+3.52%+24.82%+77.39%+18.55%+111.13%GHRSGH Research+5.01%+0.58%+20.76%-21.96%-9.66%LXEOLexeo Therapeutics+0.91%-36.31%+64.84%-39.39%-78.13%TYRATyra Biosciences+10.30%-3.91%+42.63%-20.52%-44.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.2864 of 5 stars4.61.00.00.02.10.00.6GHRSGH Research2.7869 of 5 stars4.51.00.00.02.82.50.0LXEOLexeo Therapeutics2.854 of 5 stars3.61.00.00.03.22.51.3TYRATyra Biosciences1.7129 of 5 stars3.50.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 3.14Buy$15.0028.64% UpsideGHRSGH Research 3.00Buy$30.43192.02% UpsideLXEOLexeo Therapeutics 3.17Buy$22.20725.28% UpsideTYRATyra Biosciences 3.00Buy$30.83205.58% UpsideCurrent Analyst Ratings BreakdownLatest LXEO, CRMD, GHRS, and TYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/8/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $22.004/8/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/31/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.003/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M18.19N/AN/A$1.28 per share9.11GHRSGH ResearchN/AN/AN/AN/AN/AN/ALXEOLexeo Therapeutics$650K137.38N/AN/A$4.26 per share0.63TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$46.34M-$0.33N/A12.40N/AN/A-79.21%-64.68%N/AGHRSGH Research-$35.59M-$0.75N/AN/AN/AN/A-20.29%-19.49%N/ALXEOLexeo Therapeutics-$66.39M-$3.08N/AN/AN/AN/A-57.66%-48.18%N/ATYRATyra Biosciences-$69.13M-$1.51N/AN/AN/AN/A-24.56%-23.31%N/ALatest LXEO, CRMD, GHRS, and TYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/A3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 million3/24/2025Q4 2024LXEOLexeo Therapeutics-$0.87-$0.78+$0.09-$0.78N/AN/A2/27/2025Q4 2024GHRSGH Research-$0.23-$0.17+$0.06-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A3.963.60GHRSGH ResearchN/A15.8315.83LXEOLexeo Therapeutics0.015.955.95TYRATyra BiosciencesN/A29.5529.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%GHRSGH Research56.90%LXEOLexeo Therapeutics60.67%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.20%GHRSGH Research41.60%LXEOLexeo Therapeutics4.50%TYRATyra Biosciences15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.81 million57.52 millionOptionableGHRSGH Research1052.03 million30.38 millionOptionableLXEOLexeo Therapeutics5833.20 million31.58 millionNot OptionableTYRATyra Biosciences2053.09 million42.81 millionOptionableLXEO, CRMD, GHRS, and TYRA HeadlinesRecent News About These CompaniesOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9 at 9:16 AM | finance.yahoo.com54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Acquired by Raymond James Financial Inc.May 9 at 3:27 AM | marketbeat.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8 at 4:05 PM | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6 at 11:23 PM | aaii.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by BVF Inc. ILMay 6 at 7:30 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $543,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 6 at 4:21 AM | marketbeat.com29,100 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Bought by Renaissance Technologies LLCMay 6 at 3:30 AM | marketbeat.comComparing Tyra Biosciences (NASDAQ:TYRA) & Mallinckrodt (OTCMKTS:MNKKQ)May 6 at 2:11 AM | americanbankingnews.comAlly Bridge Group NY LLC Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Buys Shares of 2,027,678 Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comMarshall Wace LLP Acquires 34,463 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Bought by RA Capital Management L.P.May 3, 2025 | marketbeat.comTyra Biosciences (TYRA) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comNantahala Capital Management LLC Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)April 30, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by JPMorgan Chase & Co.April 28, 2025 | marketbeat.comWalleye Capital LLC Sells 63,617 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)April 24, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by BrokeragesApril 19, 2025 | marketbeat.comVanguard Group Inc. Sells 37,643 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)April 19, 2025 | marketbeat.comInvestment Counsel Co. of Nevada Purchases New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA)April 16, 2025 | marketbeat.comTyra Biosciences price target lowered to $28 from $29 at BofAMarch 30, 2025 | markets.businessinsider.comTyra Biosciences reports Q4 EPS (43c) vs. (53c) last yearMarch 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXEO, CRMD, GHRS, and TYRA Company DescriptionsCorMedix NASDAQ:CRMD$11.66 -0.37 (-3.08%) As of 04:00 PM EasternCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.GH Research NASDAQ:GHRS$10.42 -0.38 (-3.52%) As of 03:58 PM EasternGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Lexeo Therapeutics NASDAQ:LXEO$2.69 -0.31 (-10.33%) As of 04:00 PM EasternLexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Tyra Biosciences NASDAQ:TYRA$10.09 +0.02 (+0.20%) As of 04:00 PM EasternTyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
